Daré Bioscience, Inc.
DARENASDAQHealthcare● Active
$1.85
$-0.03(-1.60%)
Market Cap$17615082
P/E Ratio—
52W High$9.19
52W Low$1.27
Daré Bioscience, Inc. (DARE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DARE · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.03M | $0.01M | $2.81M | $10.00M | $0.00M |
| Cost of Revenue | $2.45M | $14.31M | $21.64M | $30.14M | $0.10M |
| Gross Profit | ($1.42M) | ($14.30M) | ($18.83M) | ($20.14M) | ($0.10M) |
| Gross Margin %(computed) | -137.55% | — | -670.62% | -201.42% | — |
| Operating Expenses | |||||
| R&D Expenses | $5523.35M | $14.21M | $21.54M | $30.04M | $30.62M |
| G&A Expenses | $8.76M | $8.36M | $11.31M | $10.64M | $7.79M |
| Total Operating Expenses | $12.14M | $9.16M | $12.11M | $11.24M | $38.97M |
| Operating Income | ($13.55M) | ($23.45M) | ($30.94M) | ($31.39M) | ($39.07M) |
| Operating Margin %(computed) | — | — | — | -313.85% | — |
| Interest Income | $0.68M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.82M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($13.40M) | ($4.05M) | ($30.16M) | ($30.95M) | ($38.70M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($13.40M) | ($4.05M) | ($30.16M) | ($30.95M) | ($38.70M) |
| Net Margin %(computed) | — | — | — | -309.48% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.20 | $-0.48 | $-4.15 | $-4.39 | $-7.52 |
| Wtd Avg Shares | 111.79M | 8.50M | 7.28M | 7.05M | 5.10M |
| EBITDA | ($11.40M) | ($23.41M) | ($30.70M) | ($31.36M) | ($39.04M) |
| EBITDA Margin %(computed) | — | — | — | -313.61% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Daré Bioscience, Inc. data
About Daré Bioscience, Inc. (DARE) Income Statement
Daré Bioscience, Inc. (DARE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DARE reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -137.55%), and net income of ($0.01B) — a net profit margin of -1300.66%.
Frequently asked questions
DARE · 4 questionsDaré Bioscience, Inc. (DARE) reported revenue of $0.00B for 2025, up 10429.4% year-over-year.
DARE revenueDARE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08